Quick Dispatch:
Your surpass trial tirzepatide SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surpass trial tirzepatide SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes ships.
Need Help?
Questions about surpass trial tirzepatide SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surpass trial tirzepatide SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes in your area.
01443-4/asset/63fe4912-d57e-4c87-ad6b-1952000f93e1/main.assets/gr1_lrg.jpg)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
22.52
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity
26.55
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice
28.42
Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial
28.23
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
28.40
Effects of tirzepatide on adjudicated cardiovascular events in
20.87
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. , , Read the full SURPASS-CVOT
28.88
